Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Christine A. Iacobuzio–Donahue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4672-3023; OpenAlex author ID A5043757838; NIH RePORTER profile ID 1865744. Sources: funder_awards.

Their work

Papers
102 (first author 5, last author 19)
Trials
0
Grants
6
Labs led
2
Collaborators
357
Papers, trials and grants by year

2007: 1 grant · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: 8 papers · 2013: 7 papers, 1 grant · 2014: 6 papers · 2015: 9 papers · 2016: 11 papers, 1 grant · 2017: 8 papers · 2018: 4 papers · 2019: 6 papers · 2020: 8 papers · 2021: 5 papers · 2022: 4 papers, 1 grant · 2023: 3 papers · 2024: 4 papers, 1 grant · 2025: 4 papers · 2026: 13 papers, 1 grant

Papers 50 of 102

  1. Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.70136↗
  2. SPINK1-COL18A1 crosstalk shapes epigenome and drives cancer stemness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117806↗
  3. Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Co-author DOI 10.1016/j.devcel.2026.04.012↗
  4. FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer. Co-author DOI 10.1016/j.ejca.2026.116255↗
  5. Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model. Co-author DOI 10.1016/j.jvir.2025.107908↗
  6. Genomic evolution of pancreatic cancer at single-cell resolution. Last author DOI 10.1038/s41588-025-02468-9↗
  7. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  8. Syndecan-1 Is a Key Mediator of Entosis and Cellular Competition in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002542↗
  9. Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1117↗
  10. Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-24-0772↗
  11. Pancreatic Cancer: Translating Tumor Biology into Actionability. Co-author DOI 10.1158/2159-8290.cd-25-2014↗
  12. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  13. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  14. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  15. SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence. Co-author DOI 10.1038/s43018-025-01047-5↗
  16. The Evolutionary Forest of Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-23-1541↗
  17. The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions. Last author DOI 10.1158/2767-9764.crc-24-0167↗
  18. Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/s41591-023-02694-w↗
  19. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  20. Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-65900-w↗
  21. A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention. Co-author DOI 10.1158/2159-8290.cd-23-1323↗
  22. Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer. Last author DOI 10.1038/s41467-023-36344-z↗
  23. The war on pancreatic cancer: progress and promise. Co-author DOI 10.1038/s41575-022-00728-1↗
  24. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  25. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signali… Co-author DOI 10.1038/s41467-022-34081-3↗
  26. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Co-author DOI 10.1038/s41586-022-04735-9↗
  27. Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. Co-author DOI 10.1158/0008-5472.can-22-1742↗
  28. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  29. Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Co-author DOI 10.1038/s41467-021-23237-2↗
  30. The pancreatic cancer genome revisited. Last author DOI 10.1038/s41575-021-00463-z↗
  31. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Co-author DOI 10.1097/mpa.0000000000001762↗
  32. Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001919↗
  33. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08123-w↗
  34. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  35. Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41379-020-0549-5↗
  36. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s43018-019-0010-1↗
  37. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1920240117↗
  38. Evolutionary Dynamics of Non-Coding Regions in Pancreatic Ductal Adenocarcinoma Last author DOI 10.1101/2020.09.11.294389↗
  39. iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Co-author DOI 10.1158/0008-5472.can-19-2991↗
  40. ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0529↗
  41. The Evolutionary Origins of Recurrent Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-19-1508↗
  42. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  43. Characterization of genetic subclonal evolution in pancreatic cancer mouse models. Co-author DOI 10.1038/s41467-019-13100-w↗
  44. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Co-author DOI 10.1073/pnas.1811067116↗
  45. The Genetic Basis of Transcriptional and Spatial Heterogeneity of Squamous Features in Pancreatic Ductal Adenocarcinoma Last author DOI 10.1101/548354↗
  46. Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter? Co-author DOI 10.1158/1078-0432.ccr-18-3042↗
  47. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Co-author DOI 10.1186/s13148-019-0650-0↗
  48. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Last author DOI 10.1097/mpa.0000000000000985↗
  49. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Co-author DOI 10.1126/science.aao4908↗
  50. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗

Grants 6

  1. Biostatistics Core P50CA257881↗
  2. Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability R35CA220508↗
  3. Data Processing, Analysis and Modeling Unit U2CCA233284↗
  4. (PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer R01CA179991↗
  5. TGF-beta Signaling in Pancreatic Cancer Progression R01CA140599↗
  6. Using a Genomic Scale to Identify the Genes that Play a Role in the Ability of Pancreatic Cancer to Metastasize to Other Organs AWARD pancan:2007-christine-iacobuzio-donahue-md-phd-using-a-genomic-scale-to-identify-the-ge

Closest collaborators

The 25 strongest of 357 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 24 shared papers, 1 shared grant, 2015–2026 · strength 4.10
  2. Akimasa Hayashi · 15 shared papers, 2019–2026 · strength 2.45
  3. Jungeui Hong · 12 shared papers, 2017–2026 · strength 1.90
  4. Wungki Park · 9 shared papers, 2020–2026 · strength 1.83
  5. Alvin P. Makohon-Moore · 20 shared papers, 2013–2025 · strength 1.80
  6. Olca Baştürk · 11 shared papers, 1 shared grant, 2015–2026 · strength 1.79
  7. Marinela Capanu · 7 shared papers, 1 shared grant, 2018–2026 · strength 1.70
  8. Alice Chia-Chi Wei · 5 shared papers, 1 shared grant, 2023–2026 · strength 1.63
  9. Vinod P. Balachandran · 9 shared papers, 1 shared grant, 2017–2026 · strength 1.63
  10. Dana Pe'er · 5 shared papers, 1 shared grant, 2022–2026 · strength 1.57
  11. Laura DeLong Wood · 15 shared papers, 2013–2026 · strength 1.49
  12. Haochen Zhang · 5 shared papers, 2023–2026 · strength 1.05
  13. Caitlin A. McIntyre · 7 shared papers, 2019–2026 · strength 1.04
  14. Kevin C. Soares · 5 shared papers, 2022–2026 · strength 0.92
  15. Ralph H. Hruban · 20 shared papers, 2012–2020 · strength 0.89
  16. Kenneth H. Yu · 8 shared papers, 2015–2026 · strength 0.87
  17. Christopher Lee Wolfgang · 15 shared papers, 2012–2026 · strength 0.86
  18. Zachary A. Kohutek · 8 shared papers, 2015–2026 · strength 0.85
  19. Fiyinfolu O. Balogun · 4 shared papers, 2025–2026 · strength 0.85
  20. Steven D Leach · 10 shared papers, 2014–2026 · strength 0.82
  21. Anna M. Varghese · 7 shared papers, 2017–2026 · strength 0.80
  22. Joseph M. Herman · 16 shared papers, 2012–2018 · strength 0.77
  23. Jason Stuart Lewis · 1 shared paper, 1 shared grant, 2020–2026 · strength 0.77
  24. Marsha Reyngold · 3 shared papers, 2026 · strength 0.76
  25. Marc A. Attiyeh · 9 shared papers, 2017–2025 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.